Abstract:Pulmonary Hypertension (PH) is a life-shortening condition characterised by episodes of decompensation precipitated by factors such as disease progression, arrhythmias and sepsis. Surgery and pregnancy also place additional strain on the right ventricle. Data on critical care management in patients with pre-existing PH are scarce.We conducted a retrospective observational study of a large cohort of patients admitted to the critical care unit of a national referral centre between 2000–17 to establish acute mort… Show more
“…They have assessed our previously proposed predictive score for outcomes in medically decompensated pulmonary hypertension (PH) patients: the OPALS score (oxygen (oxygen saturation measured by pulse oximetry/inspiratory oxygen fraction ratio ⩽185), platelets ⩽196×10 9 L −1 , age ⩾37.5 years, lactate ⩾2.45 mmol·L −1 and sodium ⩽130.5 mmol·L −1 ) in 74 PH patients. Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78) [ 2 ]. Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R 2 =0.97).…”
supporting
confidence: 83%
“…Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78). 2 Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R 2 =0.97). The OPALS score therefore appears to be a promising PH-specific tool for predicting outcomes in medically-decompensated patients.…”
Section: To the Editormentioning
confidence: 96%
“…Robin Condliffe 1,2 , Kris Bauchmuller 3 , Jennifer Southern 3 , David G Kiely 1,2 and Gary H Mills 3,4 Affiliations: 1…”
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.
“…They have assessed our previously proposed predictive score for outcomes in medically decompensated pulmonary hypertension (PH) patients: the OPALS score (oxygen (oxygen saturation measured by pulse oximetry/inspiratory oxygen fraction ratio ⩽185), platelets ⩽196×10 9 L −1 , age ⩾37.5 years, lactate ⩾2.45 mmol·L −1 and sodium ⩽130.5 mmol·L −1 ) in 74 PH patients. Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78) [ 2 ]. Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R 2 =0.97).…”
supporting
confidence: 83%
“…Discriminatory power was very similar to that observed in our derivation cohort (c-statistic of 0.77 versus 0.78). 2 Furthermore, there was exceedingly high calibration between predicted and observed mortality in their validation cohort (R 2 =0.97). The OPALS score therefore appears to be a promising PH-specific tool for predicting outcomes in medically-decompensated patients.…”
Section: To the Editormentioning
confidence: 96%
“…Robin Condliffe 1,2 , Kris Bauchmuller 3 , Jennifer Southern 3 , David G Kiely 1,2 and Gary H Mills 3,4 Affiliations: 1…”
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.
“…As a distinctive disease with multiple aetiologies, pulmonary arterial hypertension (PAH) is recognized as a cause of acute and chronic right-sided heart failure (RHF), but the clinical onset of the RHF is variable among different subgroups of PAH with similar degree of pulmonary pressure [ 3 , 4 ]. Data regarding admission, management, and outcomes of PAH patients in intensive care unit (ICU) are still limited, as a result of small number of diagnosed cases and lack of consisting data [ 5 , 6 , 7 ].…”
Despite substantial advancements in diagnosis and specific medical therapy in pulmonary arterial hypertension patients’ management, this condition continues to represent a major cause of mortality worldwide. In pulmonary arterial hypertension, the continuous increase of pulmonary vascular resistance and rapid development of right heart failure determine a poor prognosis. Against targeted therapy, patients inexorable deteriorate over time. Pulmonary arterial hypertension patients with acute right heart failure who need intensive care unit admission present a complexity of the disease pathophysiology. Intensive care management challenges are multifaceted. Awareness of algorithms of right-sided heart failure monitoring in intensive care units, targeted pulmonary hypertension therapies, and recognition of precipitating factors, hemodynamic instability and progressive multisystem organ failure requires a multidisciplinary pulmonary hypertension team. This paper summarizes the management strategies of acute right-sided heart failure in pulmonary arterial hypertension adult cases based on recently available data.
“…We were very pleased to read the article “Critical care outcomes in patients with pre-existing pulmonary hypertension: insights from the ASPIRE registry”, recently published in ERJ Open Research [ 1 ].…”
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.